# Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy

> **NCT02460094** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 48 (actual)

## Conditions studied

- Progressive Supranuclear Palsy

## Interventions

- **DRUG:** BIIB092
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02460094
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-02
- **Primary completion:** 2016-10-19
- **Final completion:** 2016-10-19
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2018-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02460094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02460094, "Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02460094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*